-
Dosimetric Impact of Intrafraction Prostate Motion in Dose Escalated Linac-Based SBRT
Read articleD. Panizza,1,2 V. Faccenda,1,3 R. Lucchini,2,4 M.C. Daniotti,3 S. Trivellato,1 P. Caricato,1,3 S. Arcangeli,2,4 and E. De Ponti, 1,2;
1 ASST Monza – Medical Physics Department, Monza, Italy, 2 University of Milan Bicocca – School of Medicine and Surgery, Milan, Italy, 3 University of Milan – Department of Physics, Milan, Italy, 4 ASST Monza – Department of Radiation Oncology, Monza, Italy
-
Intrafraction Prostate Motion Management during Dose-Escalated Linac-Based SBRT
Read articleD. Panizza, V. Faccenda, R. Lucchini, M.C. Daniotti, S. Trivellato, P. Caricato, S. Arcangeli and E. De Ponti
Published in International Journal of Radiation Oncology, VOLUME 114, ISSUE 3, SUPPLEMENT , E570-E571, NOVEMBER 01, 2022
-
Intensity-modulated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): 2-year toxicity results from an open-label, randomised, phase 3, non-inferiority trial
·
Read articleAlison C Tree, Peter Ostler, Hans van der Voet, William Chu, Andrew Loblaw, Daniel Ford, Shaun Tolan, Suneil Jain, Alexander Martin, John Staffurth, John Armstrong, Philip Camilleri, Kiran Kancherla, John Frew, Andrew Chan, Ian S Dayes, Aileen Duffton, Douglas H Brand, Daniel Henderson, Kirsty Morrison, Stephanie Brown, Julia Pugh, Stephanie Burnett, Muneeb Mahmud, Victoria Hinder, Olivia Naismith, Emma Hall*, Nicholas van As*, on behalf of the PACE Trial Investigators.
-
Intrafraction Prostate Motion Management During Dose-Escalated Linac-Based Stereotactic Body Radiation Therapy
Read articleDenis Panizza 1,2*, Valeria Faccenda 1,3, Raffaella Lucchini 2,4, Martina Camilla Daniotti 1,3, Sara Trivellato1 , Paolo Caricato 1,3, Valerio Pisoni 4, Elena De Ponti 1,2 and Stefano Arcangeli 2,4
1 Medical Physics Department, ASST Monza, Monza, Italy, 2 School of Medicine and Surgery, University of Milan Bicocca, Milan, Italy, 3 Department of Physics, University of Milan, Milan, Italy, 4 Radiation Oncology Department, ASST Monza, Monza, Italy
-
Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer (HYPO-RT-PC): patient-reported quality-of-life outcomes of a randomised, controlled, non-inferiority, phase 3 trial
Read articlePer Fransson, PhD, Per Nilsson, PhD, Adalsteinn Gunnlaugsson, MD, Lars Beckman, MD, Björn Tavelin, BSc, David Norman, BSc, Camilla Thellenberg-Karlsson, MD, Prof Morten Hoyer, MD, Magnus Lagerlund, MD, Jon Kindblom, MD, Claes Ginman, MD, Bengt Johansson, MD, Kirsten Björnlinger, MD, Mihajl Seke, MD, Måns Agrup, MD, Prof Björn Zackrisson, MD, Elisabeth Kjellén, MD, Prof Lars Franzén, MD, Prof Anders Widmark, MD